Tamoxifen-induced fatty liver in patients with breast cancer

Lancet

Volumn 351, Issue 9104, 1998, Pages 725-

  Ogawa, Yasuhiro ^a   Murata, Yoriko ^b   Nishioka, Akihito ^b   Inomata, Taisuke ^b   Yoshida, Shoji ^b  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIESTROGEN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FATTY LIVER; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TIME; WEIGHT GAIN;

EID: 0032492439     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)78493-2     Document Type: Article

References (4)

1. 1 Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-18, 71-85.
2. 2 Fex G, Adielsson G. Oestrogen like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol 1981; 97: 109-13.
3. 3 Louis DB, Claude G, Cöme R. Severe lipemia induced by tamoxifen. Cancer 1986; 57: 2123-26.
4. 4 Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. Gastroenterology 1988; 95: 1056-62.